Gliclazide Use in Renal Failure

Introduction to Gliclazide in Renal Impairment

The American Journal of Kidney Diseases recommends gliclazide as a preferred second-generation sulfonylurea for patients with renal impairment, due to its lack of active metabolites, but requires substantial dose reduction in advanced CKD, close glucose monitoring, and consideration of safer alternatives like SGLT2 inhibitors or DPP-4 inhibitors 1, 2

The American Journal of Kidney Diseases advises that first-generation sulfonylureas, such as chlorpropamide, tolazamide, and tolbutamide, must be completely avoided in any degree of renal impairment due to increased half-lives and severe hypoglycemia risk 1
The Kidney International journal strongly recommends SGLT2 inhibitors for patients with eGFR ≥20 mL/min/1.73 m², due to their documented cardiovascular and kidney benefits, and lower hypoglycemia risk compared to sulfonylureas 5

For patients with eGFR 15-29 mL/min/1.73 m², the Praxis Medical Insights guideline suggests reducing the gliclazide dose by at least 50% and implementing frequent glucose monitoring, as well as considering safer alternatives like SGLT2 inhibitors or DPP-4 inhibitors 2, 5
The American Journal of Kidney Diseases recommends monitoring renal function every 2-4 weeks initially after dose adjustments, then every 3-6 months, and daily self-monitoring or continuous glucose monitoring to prevent hypoglycemia 1, 2

The Kidney International journal recommends GLP-1 receptor agonists, such as dulaglutide, when metformin and SGLT2 inhibitors cannot achieve glycemic targets, with minimal hypoglycemia risk when used alone 5
The American Journal of Kidney Diseases suggests targeting HbA1c ~7.0% for patients with advanced CKD at risk of hypoglycemia, rather than <7.0%, and balancing intensive control against hypoglycemia risk, especially in patients with limited life expectancy or significant comorbidities 1, 2